Skip to main content
Shanghai Junshi Biosciences Co., Ltd. logo

Shanghai Junshi Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 1877 ISIN · CNE100003FF7 HKEX Manufacturing
Open in API
Filings indexed 1,740 across all filing types
Latest filing 2026-06-05 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 1877

About Shanghai Junshi Biosciences Co., Ltd.

http://www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company established in 2012. It is dedicated to the discovery, development, clinical research, and commercialization of innovative therapeutics, prioritizing the creation of first-in-class and best-in-class drugs. The company utilizes a global integrated R&D system and proprietary full life cycle antibody development platform technology to build a diversified and complementary pipeline. Junshi Biosciences operates as a full-chain entity, integrating research, production, and commercialization capabilities to maintain global competitiveness in the biopharmaceutical sector.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 26 JUNE 2026
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a Form of Proxy for the 2025 Annual General Meeting, which is part of materials sent to shareholders to solicit their voting instructions ahead of the meeting. This falls under Proxy Solicitation & Information Statement (PSI).
2026-06-05 English
NOTICE OF THE 2025 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 85% confidence The document is the official notice of the company’s 2025 Annual General Meeting, detailing meeting time, venue and proposed resolutions for shareholder voting. It is sent to shareholders to provide meeting information and solicit votes, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-05 English
2025 AGM CIRCULAR
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a shareholder circular convening the 2025 AGM, containing the letter from the board, notice of meeting, resolutions to be voted on, appendices (board’s report, remuneration policies, dividend plan, etc.), and instructions for proxies. It is not the standalone annual report but rather the proxy solicitation/information statement sent to shareholders to request votes at the AGM. Therefore it best fits the Proxy Solicitation & Information Statement category (PSI).
2026-06-05 English
CONNECTED TRANSACTION - ENTERING INTO OF THE JOINT VENTURE AGREEMENT
Regulatory Filings Classification · 88% confidence The document is a Hong Kong Stock Exchange announcement disclosing a connected transaction under Chapter 14A (entering into a joint venture agreement, asset contributions, share subscription details, conditions precedent, etc.). It is not the full underlying report or an earnings release, but a regulatory announcement regarding a corporate transaction. Therefore it falls under the generic “Regulatory Filings” category.
2026-06-05 English
CLOSURE OF REGISTER OF MEMBERS OF H SHARES
Declaration of Voting Results & Voting Rights Announcements Classification · 75% confidence The document is an announcement by the Board of Shanghai Junshi Biosciences regarding the closure of the H‐share register and the record date for determining shareholders’ voting rights at the upcoming Annual General Meeting. This is a Voting Rights Announcement rather than financial results, dividends, or a full report. It fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-05 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON CHANGE IN SHAREHOLDING STRUCTURE OF IMPLEMENTING ENTITY OF CERTAIN SUB-PROJECTS UNDER THE INVESTMENT PROJECTS
Share Issue/Capital Change Classification · 90% confidence The document is an overseas regulatory announcement under HKEx Rule 13.10B detailing a capital increase and share expansion transaction that changes the shareholding structure of a subsidiary. It is not a general earnings release, AGM material, proxy, or financial report, but a corporate action notice regarding a new share issuance and capital structure change. This aligns with the “Share Issue/Capital Change” category.
2026-06-05 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.